Deep brain stimulation for primary generalized dystonia: long-term outcomes

Area of Science:

• Neurology
• Neurosurgery
• Biomedical Engineering

Background:

• Pallidal deep brain stimulation (DBS) is a primary treatment for medication-refractory primary generalized dystonia (PGD).
• Long-term efficacy and safety data for pallidal DBS in PGD patients remain limited.

Purpose of the Study:

• To evaluate the long-term clinical outcomes of pallidal DBS in patients with primary generalized dystonia.
• To assess the safety and durability of pallidal DBS over an extended follow-up period.

Main Methods:

• A case series design was employed at a university hospital.
• Thirty consecutive patients with PGD received pallidal DBS and underwent annual follow-up for up to 8 years.
• Clinical outcomes were assessed using the Burke-Fahn-Marsden dystonia scale, adverse event monitoring, and device parameters.

Main Results:

• Sustained clinical improvement was observed at all annual follow-up examinations up to 8 years.
• No intraoperative complications occurred; hardware-related adverse events were infrequent, with rare stimulation-related events affecting speech.
• Lower stimulation frequencies (60 Hz) significantly extended implantable pulse generator longevity compared to higher frequencies (130 Hz), with no impact on clinical outcomes.

Conclusions:

• Pallidal DBS is a safe and effective long-term treatment for primary generalized dystonia.
• Sustained improvements in dystonia symptoms can be maintained for up to 8 years.
• Optimizing stimulation parameters to lower energy levels can enhance device longevity without compromising therapeutic efficacy.